Novartis AG Cash Flow-to-Debt Ratio
Novartis AG cash flow-to-debt ratio. Novartis AG (NVSN) has a Cash Flow-to-Debt Ratio of 0.05x as of March 2026, meaning its operating cash flow of MX$3.68 Billion could theoretically repay 0% of its total liabilities (MX$79.61 Billion) in one year. Check Novartis AG (NVSN) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Novartis AG (2014–2025)
Cash flow-to-debt ratio of Novartis AG from 2014 to 2025. Historical debt coverage capacity for Novartis AG across 12 annual periods. Check Novartis AG total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Novartis AG Cash Flow-to-Debt Ratio by Year (2014–2025)
Novartis AG cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Novartis AG. For the full cash flow conversion analysis, see cash flow conversion of Novartis AG.
| Year | CF-to-Debt Ratio | Operating CF (MXN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | MX$19.14 Billion | MX$64.40 Billion | ▼ -1.9% |
| 2024 | 0.30x | MX$17.62 Billion | MX$58.12 Billion | ▲ +0.6% |
| 2023 | 0.30x | MX$16.02 Billion | MX$53.20 Billion | ▲ +22.8% |
| 2022 | 0.25x | MX$14.24 Billion | MX$58.03 Billion | ▲ +4.1% |
| 2021 | 0.24x | MX$15.07 Billion | MX$63.97 Billion | ▲ +30.1% |
| 2020 | 0.18x | MX$13.65 Billion | MX$75.39 Billion | ▼ -16.5% |
| 2019 | 0.22x | MX$13.62 Billion | MX$62.82 Billion | ▲ +1.6% |
| 2018 | 0.21x | MX$14.27 Billion | MX$66.87 Billion | ▼ -0.5% |
| 2017 | 0.21x | MX$12.62 Billion | MX$58.85 Billion | ▲ +3.2% |
| 2016 | 0.21x | MX$11.47 Billion | MX$55.23 Billion | ▼ -4.9% |
| 2015 | 0.22x | MX$11.90 Billion | MX$54.43 Billion | ▼ -14.2% |
| 2014 | 0.25x | MX$13.90 Billion | MX$54.54 Billion | — |